Perspective Therapeutics To Discuss Data On [212Pb]VMT-α-NET Presented At The 2024 NANETS Multidisciplinary NET Medical Symposium On November 21, 2024
Perspective Therapeutics To Discuss Data On [212Pb]VMT-α-NET Presented At The 2024 NANETS Multidisciplinary NET Medical Symposium On November 21, 2024
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 21-23, 2024 in Chicago.
Perspective Therapeutics, Inc.（「Perspective」 或 「公司」）（紐約證券交易所代碼：CATX）是一家開創全身癌症先進治療應用的放射性製藥公司，今天公佈了公司贊助的 [212Pb] VMT-α-net的1/2a期試驗的初步結果的詳細信息，該研究將在2024年北美神經內分泌腫瘤學會（NANETS）多學科神經內分泌腫瘤學會（NANETS）多學科nET醫學研討會上公佈 2024 年 11 月 21 日至 23 日在芝加哥舉行。
The presentation entitled "Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs)" will be presented by Richard L. Wahl, MD, (Professor of Radiology, Mallinckrodt Institute of Radiology at Washington University School of Medicine) on Friday, November 22, 2024 at 9:05 am CT. Results of the study are also available as a poster (number C-37) at the NANETS symposium.
2024年11月22日星期五上午9點05分，醫學博士理查德·瓦爾（華盛頓大學醫學院馬林克羅特放射學教授）將發表題爲 「[212Pb] VMT-α-NET在表達神經內分泌腫瘤（NET）的生長抑素受體2（SSTR2）中的初步安全性和有效性數據」 的演講。該研究的結果也可在NANETS研討會上以海報（編號C-37）的形式公佈。
